#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Neuropathy peripheral Hairy cell leukaemia Neurotrophic keratopathy Short stature Vaginal cancer Piriformis syndrome SAPHO syndrome Progressive familial intrahepatic cholestasis Central nervous system lymphoma Rett syndrome Pulmonary hypertension Acute myeloid leukaemia Niemann-Pick disease Adenoid cystic carcinoma Neuroendocrine cell hyperplasia of infancy More trials…

    Learn about Rare Diseases

    Leukoencephalopathy – Treatment Nodal marginal zone B-cell lymphoma – Life with Disease Synovial sarcoma metastatic – Diagnostics Fabry’s disease – Basic Information Factor IX deficiency – Life with Disease Anaplastic thyroid cancer – Life with Disease Alagille syndrome Burkitt’s lymphoma – Diagnostics Alexander disease – Life with Disease Wiskott-Aldrich syndrome – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Captopril Contezolid Sodium Thiosulfate Ima203Cd8 Rosuvastatin Minzasolmin [18F]-Altanserin AAV9-CTNT-COBAG3 Vincristine ALKYLATING AGENTS Pamidronate Disodium ABIRATERONE DECANOATE GSK4524101A Elinzanetant Sarilumab Mk-4830 Rbl015.2 Fluorodopa (18F) Ds-2325A GSK3862995B More therapies…

    Learn about Your Condition

    HER2 positive breast cancer Acoustic neuroma Bacteraemia Post procedural infection Myotonia Vulvovaginal candidiasis Malignant oligodendroglioma Prostatitis Escherichia coli Immune-mediated enterocolitis Nephroblastoma Thyroid disorder Propionic acidaemia Renal disorder Hyperphagia Acute HIV infection More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centre Hospitalier Sud Francilien

Centre Hospitalier Sud Francilien

40 Avenue Serge Dassault, Corbeil Essonnes, 91106, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study of tocilizumab compared to placebo in patients with chronic chondrocalcinosis who did not respond to standard treatments

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    • Chondrocalcinosis
    Investigated Drugs:
    • Sodium Chloride
    • Tocilizumab
    France

  • Study on Stopping Allopurinol or Febuxostat in Gout Patients in Remission

    Not yet recruiting

    2 1 1 1
    Investigated Drugs:
    • Allopurinol
    • Febuxostat
    France

  • Study on Etoposide for Patients with Severe Hemophagocytic Lymphohistiocytosis in Intensive Care

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Haemophagocytic lymphohistiocytosis
    Investigated Drugs:
    • Etoposide
    France

  • Study on Multiple Myeloma Treatment with Isatuximab, Lenalidomide, and Carfilzomib for Patients Under 66 Eligible for Stem Cell Transplant

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Iberdomide
    • Isatuximab
    • Carfilzomib
    Belgium France

  • Study on Switching from Dulaglutide to Tirzepatide for Adults with Type 2 Diabetes

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Bromocriptine
    • Colesevelam
    • Dimeticone
    Belgium France Germany Romania

  • A study of ziltivekimab compared to placebo for reducing heart problems in patients who have had a heart attack

    Not recruiting

    3 1
    Investigated Diseases:
    • Acute myocardial infarction
    Investigated Drugs:
    • Ziltivekimab
    Bulgaria Czechia Denmark France Germany Greece +4

  • Study of cisplatin, gemcitabine and rilvegostomig treatment in patients with high-risk resectable intrahepatic cholangiocarcinoma

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Cholangiocarcinoma
    Investigated Drugs:
    • Cisplatin
    • Gemcitabine
    • Rilvegostomig
    France

  • Study on Chemotherapy with Levoleucovorin, Capecitabine, and Folinic Acid for Patients Aged 70+ After Stage III Colon Cancer Surgery

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Colon cancer
    Investigated Drugs:
    • Levoleucovorin
    • Capecitabine
    • Fluorouracil
    Belgium France

  • Study on the Effects of Propofol Sedation in Preterm Babies with Respiratory Distress Syndrome During LISA Procedure

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Neonatal respiratory distress syndrome
    Investigated Drugs:
    • Ketamine Hydrochloride
    • Propofol
    • Soya Oil
    France

  • Study of rituximab and belimumab combination compared to rituximab alone in adults with persistent or chronic immune thrombocytopenia (ITP)

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Belimumab
    France
Previous Page
1 … 3 4 5 6 7 8
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!